Pitrakinra

Pitrakinra is a recombinant protein that is designed to be a selective antagonist of the interleukin-4 receptor. It is used in the treatment of asthma and allergic diseases. The drug was developed by Aerovance, a biopharmaceutical company based in Berkeley, California.

Etymology[edit | edit source]

The name "Pitrakinra" is derived from the Greek words "pitra", meaning "against", and "kinra", meaning "movement". This reflects the drug's function as an antagonist, working against the movement of certain proteins in the body.

Mechanism of Action[edit | edit source]

Pitrakinra works by binding to the interleukin-4 receptor, preventing the binding of interleukin-4 and interleukin-13, two cytokines that are involved in the inflammatory response in asthma and allergic diseases. By blocking these cytokines, Pitrakinra reduces inflammation and improves symptoms.

Clinical Trials[edit | edit source]

Pitrakinra has been tested in several clinical trials. In a Phase II trial, the drug was found to significantly reduce asthma symptoms and improve lung function in patients with moderate to severe asthma. In another trial, Pitrakinra was found to be effective in reducing symptoms in patients with atopic dermatitis, a type of allergic skin disease.

Side Effects[edit | edit source]

Common side effects of Pitrakinra include injection site reactions, upper respiratory tract infections, and headache. Serious side effects can include severe allergic reactions.

See Also[edit | edit source]

Pitrakinra Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.